MOG (35-55): Gold Standard Peptide for Experimental Autoimmune Encephalomyelitis Modeling

Executive Summary: MOG (35-55) is a synthetic peptide corresponding to amino acids 35–55 of the human myelin oligodendrocyte glycoprotein (MOG), crucial for inducing experimental autoimmune encephalomyelitis (EAE) in murine models of multiple sclerosis (MS) (Xu et al., 2025). The peptide triggers robust T and B cell immune responses and enables reproducible, relapsing-remitting neurological disease in susceptible mouse strains (immunoglobulin-m-heavy-chain.com). MOG (35-55) activation leads to increased NADPH oxidase and MMP-9 activity, linking it to oxidative stress and matrix remodeling pathways. The peptide is benchmarked for solubility (≥32.25 mg/mL in water, ≥86 mg/mL in DMSO), and induces dose-dependent MS-like symptoms in vivo. APExBIO supplies MOG (35-55), SKU A8306, as a research-grade reagent for neuroinflammation and autoimmune disease modeling (APExBIO).

Biological Rationale

MOG (35-55) is a truncated peptide derived from the extracellular domain of human myelin oligodendrocyte glycoprotein, a member of the immunoglobulin superfamily (Xu et al., 2025). MOG is predominantly expressed on the surface of oligodendrocytes and the outermost myelin sheaths in the central nervous system (CNS). Autoimmune targeting of MOG epitopes is implicated in demyelinating disorders, most notably multiple sclerosis. The 35–55 region of MOG contains a dominant T cell epitope that is highly encephalitogenic in mice, making it a preferred tool to induce EAE, an animal model that closely mimics the immunopathology of human MS (MHC Class II Antigen). By administering MOG (35-55) with complete Freund's adjuvant (CFA), researchers reproducibly trigger neuroinflammation, demyelination, and blood-brain barrier breakdown.

Mechanism of Action of MOG (35-55)

Upon subcutaneous injection with CFA, MOG (35-55) is taken up by antigen-presenting cells (APCs). The peptide is processed and presented via MHC class II molecules to naïve CD4+ T cells. This primes autoreactive T helper (Th1 and Th17) cells, which migrate to the CNS. CNS infiltration results in the release of pro-inflammatory cytokines (e.g., IFN-γ, IL-17), activation of resident microglia, and recruitment of additional immune cells. B cell activation and autoantibody generation against MOG further amplify demyelination. In vitro, MOG (35-55) decreases protein concentration in a dose-dependent manner and upregulates NADPH oxidase and MMP-9 activity, indicating a direct role in oxidative stress and matrix remodeling (APExBIO). Recent studies demonstrate that EAE induced by MOG (35-55) is modulated by type I interferon signaling; for example, PARP7 inhibition stabilizes STAT1/STAT2 and attenuates EAE severity, linking MOG-driven pathology to interferon regulatory pathways (Xu et al., 2025).

Evidence & Benchmarks

• MOG (35-55) (A8306) reliably induces EAE with relapsing-remitting symptoms and extensive demyelination in C57BL/6 and HLA-DR2-transgenic mice (DOI:10.1016/j.celrep.2025.116130).
• Subcutaneous administration at 50–150 μg per mouse, with CFA, produces dose-dependent disease severity and weight loss (see product protocol, APExBIO).
• The peptide is soluble at ≥32.25 mg/mL in water and ≥86 mg/mL in DMSO, but insoluble in ethanol (product technical data, APExBIO).
• MOG (35-55) increases NADPH oxidase and MMP-9 activity in vitro, implicating oxidative stress and matrix remodeling as pathogenic mechanisms (Xu et al., 2025).
• PARP7 inhibition ameliorates EAE severity in MOG (35-55)-induced models by stabilizing STAT1/2 and enhancing type I interferon signaling (Xu et al., 2025).
• APExBIO’s MOG (35-55) is validated for lot-to-lot reproducibility and protocol compatibility (immunoglobulin-m-heavy-chain.com).

Applications, Limits & Misconceptions

MOG (35-55) is the benchmark inducer for EAE in MS research and is widely used to evaluate immunomodulatory therapies, neuroinflammation, and demyelinating mechanisms. It is suitable for:

• Induction of EAE in C57BL/6, SJL/J, and HLA-DR2-transgenic mice.
• Assessment of T and B cell-dependent autoimmune responses.
• Study of CNS demyelination, blood-brain barrier integrity, and neuroinflammatory signaling.
• Screening of candidate immunotherapies in preclinical settings.

For in-depth troubleshooting and advanced workflow strategies, see this guide, which this article extends by providing updated mechanistic and benchmark details from the latest literature.

Common Pitfalls or Misconceptions

• MOG (35-55) does not induce EAE in all mouse strains; genetic background strongly influences susceptibility.
• Peptide solubility in ethanol is negligible; use only water or DMSO as solvents as per technical datasheet (APExBIO).
• Stock solutions degrade rapidly at room temperature; always store desiccated at -20°C and use promptly.
• MOG (35-55) cannot model all aspects of human MS; it is optimal for T cell- and B cell-mediated demyelination, but does not recapitulate all progressive MS forms (ku55933.com extends this by discussing translational gaps).
• Autoimmune responses are adjuvant-dependent; omission or substitution of CFA reduces model reliability.

Workflow Integration & Parameters

For experimental use, dissolve MOG (35-55) at 0.50 mg/mL in sterile water, applying mild warming and ultrasonic bath if required. Avoid ethanol. Prepare aliquots, store desiccated at -20°C, and avoid freeze-thaw cycles. Typical in vivo dosing is 50–150 μg/mouse, administered subcutaneously with CFA and pertussis toxin as per established EAE protocols (immunoglobulin-m-heavy-chain.com). For a detailed, scenario-driven protocol comparison, see this dossier, which this article clarifies with new mechanistic and benchmarking links to type I IFN signaling.

Conclusion & Outlook

MOG (35-55) is a validated, reproducible reagent for inducing EAE and modeling multiple sclerosis in preclinical research. Its biological activity is tightly linked to T and B cell activation, CNS demyelination, and neuroinflammation. Integration of MOG (35-55) with new mechanistic insights—such as interferon pathway modulation via PARP7—enables advanced studies of autoimmune pathogenesis and therapeutic targets (Xu et al., 2025). Researchers are advised to use APExBIO’s A8306 MOG (35-55) for benchmarked consistency and protocol compliance (product page).